AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8824652
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole o.m.
Trial: 8824652
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg omeprazole o.m.
Trial: 2129633
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of omeprazole
Trial: 2129633
Drug: Drug-induced hypochlorhydria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-induced hypochlorhydria
Trial: 21247663
Drug: Polysporin first‐aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysporin first‐aid ointment (Poly/Bac)
Trial: 19570440
Drug: Motherwort injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motherwort injection (40 mg uterine injection during CS and 20 mg intramuscular injection per 12 hours 3 times after CS)
Trial: 19570440
Drug: Motherwort +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motherwort + Oxytocin (40 mg motherwort and 10 U oxytocin uterine injection during CS; 20 mg motherwort intramuscular injection per 12 hours 3 times after CS)
Trial: 19570440
Drug: Oxytocin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (10 U uterine injection and 10 U+5% glucose 500 ml intravenously during operation; 10 U intramuscular injection per 12 hours 3 times after CS)
Trial: 19570440
Drug: Motherwort injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motherwort injection
Trial: 15928300
Drug: 8 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 Gy in one treatment fraction
Trial: 15928300
Drug: 30 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 Gy in 10 treatment fractions
Trial: 12711105
Drug: Chloroquine 25
RxNorm normalized name: chloroquine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 25 mg base/kg given unsupervised by mothers at home
Trial: 12711105
Drug: Chloroquine 25
RxNorm normalized name: chloroquine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 25 mg base/kg given supervised at a health centre
Trial: 8911949
Drug: Pilocarpine TDS
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine TDS (30 mg)
Trial: 1921686
Drug: Diltiazem (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (180 mg) and Propranolol (80 mg)
Trial: 1921686
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug (Diltiazem and Propranolol) after placebo
Trial: 7029290
Drug: Adriamycin (ADR)
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin (ADR) 30 mg/m2/day for 3 successive days every 4 weeks for 6 courses
Trial: 7029290
Drug: Alternating Adriamycin
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alternating Adriamycin (ADR) and high-dose methotrexate followed by citrovorum factor rescue (HDMTX-CFR)
Trial: 27707001
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of fentanyl citrate and propofol lipid emulsion (PLE)
Trial: 27707001
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of fentanyl citrate and propofol lipid emulsion (PLE)
Trial: 18564281
Drug: 0.05% capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% capsaicin gel applied once daily for 5 months
Trial: 18564281
Drug: Vehicle (control)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (control) applied once daily for 5 months
Trial: 12220694
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with folic acid and vitamin B12
Trial: 7709405
Drug: CGS 19755
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 19755 (1.5 mg/kg)
Trial: 7709405
Drug: CGS 19755
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 19755 (2 mg/kg)
Trial: 7709405
Drug: CGS 19755
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 19755 (1.75 mg/kg)
Trial: 7709405
Drug: CGS 19755
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 19755 (1.0 mg/kg)
Trial: 7709405
Drug: CGS 19755
RxNorm normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS 19755 (all doses)
Trial: 620896
Drug: Glucagon, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon, 2 mg given intravenously before aspirin instillation
Trial: 620896
Drug: Glucagon, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon, 2 mg given intravenously
Trial: 620896
Drug: Aspirin, 600
RxNorm normalized name: Aspirin, 600 mg rectal suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 600 mg suspended in 100 ml of isotonic saline
Trial: 31200945
Drug: Oral protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral protein supplementation (30 grams of whey, three days/week during dialysis)
Trial: 31200945
Drug: Protein plus
RxNorm normalized name: Nutritional Supplement Oral Tablet [SAMSON PROTEIN PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein plus exercise (30-45 minutes of cycling during dialysis treatment, three days/week)
Trial: 21104227
Drug: Alendronate (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (35 mg weekly)
Trial: 21104227
Drug: Elcatonin (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elcatonin (intramuscular 20 units a week)
Trial: 19059753
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Group Therapy with Attention Training (CBGT + ATT)
Trial: 15509131
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg and HCTZ 12.5 mg once daily (n=46)
Trial: 15509131
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg alone once daily (n=46)
Trial: 3316516
Drug: Polychemotherapy as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polychemotherapy as initial therapy
Trial: 3316516
Drug: Single new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single new drug
Trial: 23386757
Drug: Intralesional steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional steroids
Trial: 30227659
Drug: Tocovid 200
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tocovid 200 mg twice a day
Trial: 27613934
Drug: Active progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active progesterone (PRO; 200mg twice a day)
Trial: 18085502
Drug: Levothyroxine (LT4)
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (LT4) treatment for 6 months
Trial: 9536981
Drug: Sequential compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential compression devices (Group 1)
Trial: 9536981
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin (Group 2)
Trial: 8021331
Drug: Diltiazem CD
RxNorm normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem CD 300 mg
Trial: 4900147
Drug: Topical ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ampicillin powder
Trial: 4900147
Drug: Topical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo powder (lactose)
Trial: 20006256
Drug: Intrathecal baclofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal baclofen (100 mcg)
Trial: 17171539
Drug: Family‐based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family‐based cognitive behavioural treatment for anxiety
Trial: 11340513
Drug: Topical 10%
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 10% povidone-iodine solution applied on the periocular skin and 5% povidone-iodine solution instilled on the forniceal conjunctiva the day before and one hour before surgery.
Trial: 3295676
Drug: Meclofenamate therapy
RxNorm normalized name: meclofenamate
DrugBank: Meclofenamic acid (DB00939)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meclofenamate therapy
Trial: 31046405
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg/d for 3 days, then 250 mg/2 days for 3 months)
Trial: 3320880
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 10 mg intramuscular morphine and 10 mg oral cocaine
Trial: 3320880
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of morphine and cocaine
Trial: 20432354
Drug: Magnetic resonance
RxNorm normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetic resonance angiography (MRA) using 20 mL of gadobenate dimeglumine
Trial: 17257431
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied 3 times a week for 4 weeks
Trial: 11806480
Drug: Acid-etching with
RxNorm normalized name: Q-Gel with Lipoic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid-etching with 35% phosphoric acid gel
Trial: 9486674
Drug: Moclobemide 450
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 450 mg/day + topical corticosteroid (diflucortolone valerate) for 6 weeks
Trial: 9486674
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + topical corticosteroid (diflucortolone valerate) for 6 weeks
Trial: 16856320
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (90 mg)
Trial: 3143511
Drug: Transdermal patches
RxNorm normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patches containing 0.2 mA electrical current (active)
Trial: 3143511
Drug: Transdermal patches
RxNorm normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patches containing no electrical current (passive)
Trial: 31387381
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment (n = 27 feet) with foot-ankle-hip exercise program, myofascial releasing, and joint and soft tissue mobilization techniques, twice a week for 8 weeks.
Trial: 24554545
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (TIVA) with propofol, ketamine, and dexmedetomidine
Trial: 22397344
Drug: Community care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community care (CC) group
Trial: 20089952
Drug: Oral fingolimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fingolimod 0.5 mg daily
Trial: 20089952
Drug: Oral fingolimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fingolimod 1.25 mg daily
Trial: 17592343
Drug: 4 mg/d
RxNorm normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/d of recombinant human growth hormone (r-hGH) for 12 weeks
Trial: 17592343
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of r-hGH on alternate days for maintenance (weeks 12-36)
Trial: 17533709
Drug: School-based oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based oral health education program
Trial: 10561055
Drug: MSSW with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSSW with 0.2 g/L mineral content
Trial: 10561055
Drug: MSSW with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSSW with 0.45 g/L mineral content
Trial: 10561055
Drug: MSSW with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSSW with 5 g/L mineral content
Trial: 10561055
Drug: MSSW with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSSW with 11 g/L mineral content
Trial: 6350412
Drug: Plc (traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plc (traditional pilocarpine salt solution)
Trial: 31382136
Drug: High-dose prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prednisone monotherapy (60 mg/day)
Trial: 31382136
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high-dose prednisone and moderate-dose topiramate (5 mg/kg/day)
Trial: 16036029
Drug: Beta-blockers (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (specific dosage not mentioned)
Trial: 16036029
Drug: Suboptimal doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suboptimal doses of beta-blockers
Trial: 16036029
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of beta-blockers (target doses from large-scale studies)
Trial: 12585015
Drug: Optimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal treatment early in psychosis
Trial: 10467265
Drug: Approximately 0.34T,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 0.34T, 30 stimuli, twice a day
Trial: 10467265
Drug: Approximately 0.57T,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 0.57T, 30 stimuli, twice a day
Trial: 10467265
Drug: Approximately 0.80T,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 0.80T, 30 stimuli, twice a day
Trial: 7589044
Drug: pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pravastatin 40 mg o.d. for 8 weeks
Trial: 1701029
Drug: A‐64077 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A‐64077 (800 mg)
Trial: 27311618
Drug: Vigorous intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigorous intravenous fluid resuscitation (IVFR) with lactated Ringer's solution (initial bolus of 10 mL/kg before the procedure, 3 mL/kg/h during the procedure, for 8 hours after the procedure, and a post‐procedure bolus of 10 mL/kg)
Trial: 27311618
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous fluid resuscitation (IVFR) with lactated Ringer's solution at 1.5 mL/kg/h during and for 8 hours after the procedure
Trial: 20094804
Drug: Overall change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall change in daily UI episodes
Trial: 17007699
Drug: Problem-solving treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving treatment for primary care (PST-PC) combined with elements from motivational interviewing
Trial: 11051189
Drug: Intraperitoneal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal bupivacaine (100 mg in 50 cc of saline)
Trial: 31061021
Drug: Current clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current clinical practice (300 U/mL)
Trial: 31061021
Drug: NMJ-targeted injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMJ-targeted injection (100 U/mL)
Trial: 30594222
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) 162 mg administered subcutaneously once weekly for 24 weeks
Trial: 30594222
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously once weekly for 24 weeks
Trial: 27391223
Drug: Amlodipine, Chlorthalidone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine, Chlorthalidone, or Lisinopril (antihypertensive treatment)
Trial: 22471345
Drug: Tacrolimus 1.5-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 1.5-3 ng/ml
Trial: 22471345
Drug: Tacrolimus 4-7
RxNorm normalized name: tacrolimus 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 4-7 ng/ml
Trial: 10886047
Drug: Effervescent ranitidine
RxNorm normalized name: ranitidine Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent ranitidine 150 mg b.d.
Trial: 10886047
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate antacids
Trial: 9376042
Drug: Pentoxifylline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1 mg/kg/h after a priming dose of 1 mg/kg)
Trial: 9376042
Drug: Gamma-hydroxybutyrate (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma-hydroxybutyrate (25 mg/kg/h after a priming dose of 25 mg/kg)
Trial: 8322373
Drug: Recombinant tissue‐type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant tissue‐type plasminogen activator (0.85 mg/kg) within 90 minutes
Trial: 8322373
Drug: Recombinant tissue‐type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant tissue‐type plasminogen activator (0.85 mg/kg) from 91 to 180 minutes
Trial: 3539623
Drug: Sustained-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release verapamil 200 mg once daily
Trial: 3539623
Drug: Sustained-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release verapamil 200 mg twice daily
Trial: 31061057
Drug: Conventional training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional training (maximal pelvic floor muscle contraction assessed by digital rectal examination)
Trial: 31533823
Drug: Yoga therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga therapy (60 min sessions for 8 weeks)
Trial: 26863442
Drug: SHAM (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHAM (0.1 g·kg(‐1) NaCl, 4 mL·kg(‐1) carbonated water, and 1 mL·kg(‐1) squash)
Trial: 26863442
Drug: PLA (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLA (0.1 g·kg(‐1) sodium chloride (NaCl), 4 mL·kg(‐1) tap water, and 1 mL·kg(‐1) squash)
Trial: 24736440
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of zidovudine
Trial: 22648714
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone intake of ≥10 mg/d
Trial: 17891596
Drug: Dydrogesterone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone (10 mg/day on days 1-14)
Trial: 9526519
Drug: Supranormal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supranormal oxygen delivery and consumption therapy (volume expansion and dobutamine 3 to 15 micrograms/kg/min for 12 hours)
Trial: 9526519
Drug: Normal hemodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal hemodynamic values therapy (control group)
Trial: 2498513
Drug: Gold sodium
RxNorm normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold sodium thiomalate (GSTM) 50 mg IM weekly + placebo
Trial: 2498513
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 12.5 mg weekly (oral and noncycled) + placebo
Trial: 2498513
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (GSTM and MTX)
Trial: 31168085
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (specific dosage and duration not mentioned)
Trial: 19472437
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination containing acetylsalicylic acid, paracetamol, and caffeine (randomized phase)
Trial: 19472437
Drug: Single agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agents acetylsalicylic acid and paracetamol (randomized phase)